8-K: Senseonics Reports Record 2025 Revenue, Strong 2026 Outlook

Senseonics Holdings, Inc. announced preliminary unaudited record revenue for Q4 and full year 2025, alongside robust 2026 guidance and key operational advancements.

Summary

• Preliminary unaudited revenue for the fourth quarter of 2025 was approximately $14.2 million, marking a 71% increase year-over-year.
• Preliminary unaudited revenue for the full year ended December 31, 2025, reached approximately $35.2 million, an increase of 57% year-over-year, representing the largest quarterly and annual revenue in company history.
• The unaudited balance of cash, cash equivalents, and restricted cash as of December 31, 2025, is expected to be approximately $94.3 million.
• The U.S. patient base increased by 103% in the fourth quarter of 2025 compared to the fourth quarter of 2024, driven by direct-to-consumer marketing efforts, marking the largest new patient addition in company history.
• Secured Investigational Device Exemption (IDE) approval from the FDA to commence a pivotal trial for the self-powered battery-enabled Gemini sensor, with the first patients already enrolled.
• First commercial patients are now using pump partner Sequels twiist insulin delivery system with Eversense 365 compatibility.
• Executed agreements with Ascensia Diabetes Care to take over commercialization and distribution of Eversense in the U.S., effective January 1, 2026.
• Provided full-year 2026 global net revenue guidance of approximately $58-$62 million, representing a 65% to 76% increase over 2025 revenue, reflecting the commercialization transition.
• Gross margin is expected to be approximately 50% for the full year 2026.

Sentiment

Score: 9

Explanation: The filing indicates very strong performance with record revenue and patient growth, coupled with robust 2026 guidance and significant operational milestones like FDA approval for a new sensor and strategic commercialization changes. The positive outlook and strong financial position contribute to a highly favorable sentiment.

Positives

• Achieved preliminary unaudited fourth quarter 2025 revenue of approximately $14.2 million, a 71% year-over-year increase.
• Reported preliminary unaudited full year 2025 revenue of approximately $35.2 million, a 57% year-over-year increase, marking the largest quarterly and annual revenue in company history.
• Experienced 103% new patient growth in the U.S. during Q4 2025 compared to Q4 2024, driven by successful direct-to-consumer marketing.
• Secured FDA IDE approval and commenced a pivotal trial for the self-powered battery-enabled Gemini sensor.
• Successfully integrated Eversense 365 with Sequels twiist insulin delivery system, with first commercial patients now using it.
• Transitioned Eversense commercialization and distribution rights from Ascensia Diabetes Care in the U.S. effective January 1, 2026, expected to lead to higher revenue and improved gross margins.
• Issued strong full-year 2026 global net revenue guidance of $58-$62 million, projecting a 65% to 76% increase over 2025.
• Anticipates a gross margin of approximately 50% for the full year 2026.

Risks

• Uncertainties inherent in the financial close process for the 2025 financial statements and their audit by the independent registered public accounting firm.
• Uncertainties inherent in the transition of commercial responsibility for Eversense from Ascensia.
• Uncertainties in insurer, regulatory, and administrative processes and decisions.
• Uncertainties inherent in the development, registration, and roll-out of new technology and solutions.
• Uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties.
• Uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics and its partners activities.
• Uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs.

Future Outlook

Senseonics expects full-year 2026 global net revenue to be approximately $58-$62 million, an increase of 65% to 76% over 2025, driven by the transition of Eversense commercialization from Ascensia. Gross margin is projected to be around 50% for 2026. The company anticipates an anticipated CE mark in Europe for Eversense 365, the launch of the twiist system with full Eversense compatibility, and the completion of the Gemini trial in the second half of 2026.

Management Comments

• "We closed a successful 2025 on a high note, achieving by far our highest revenue quarter as our DTC efforts continue to drive an increasing number of patients to the worlds first and only year-long CGM."
• "We now look ahead to a 2026 that should bring more exciting developments for Senseonics, most notably the transition of commercial and distribution rights to Eversense 365 from Ascensia, which we expect will lead to higher revenue and improved gross margins."
• "We also expect a boost from an anticipated CE mark in Europe for Eversense 365, the launch of the twiist system with full Eversense compatibility, and the completion of the Gemini trial in the second half of 2026."
• "Taken together, we look forward to building on the momentum we established in 2025 to drive increased shareholder value in 2026 and beyond."

Industry Context

This announcement positions Senseonics as a growing player in the continuous glucose monitoring (CGM) market, a sector experiencing significant expansion due to increasing diabetes prevalence and demand for advanced management tools. The substantial patient growth driven by direct-to-consumer marketing indicates effective market penetration strategies, aligning with broader industry trends of companies seeking direct engagement with end-users. The strategic decision to take over commercialization from Ascensia suggests a move to capture greater value and control over its distribution channels, a common strategy for maturing medical technology companies aiming to optimize profitability and market presence. New product developments like the Gemini sensor and integration with insulin pump systems (twiist) reflect the ongoing innovation and convergence of diabetes management technologies.

Stakeholder Impact

• Shareholders: Likely positive impact due to record revenue, strong growth, and optimistic future guidance, potentially leading to increased share value.
• Patients: Positive impact through expanded access to Eversense CGM systems due to increased commercialization efforts and the development of new technologies like the Gemini sensor and integration with pump systems.
• Employees: Potential positive impact from company growth and expansion, possibly leading to new opportunities.
• Ascensia Diabetes Care: Their role is transitioning from commercialization and distribution partner in the U.S. to a more focused collaboration, with European agreements still being finalized.

Next Steps

• Finalize 2025 financial statements and complete the audit by the independent registered public accounting firm.
• Report fourth quarter and full year 2025 financial results after market close on March 2, 2026.
• Hold a conference call to review Q4 and full year 2025 performance on March 2, 2026, at 4:30 p.m. Eastern Time.
• Finalize agreements with Ascensia for the transition of European sales and marketing infrastructure to Senseonics.
• Anticipate receiving a CE mark in Europe for Eversense 365.
• Launch the twiist system with full Eversense compatibility.
• Complete the pivotal trial for the self-powered battery-enabled Gemini sensor in the second half of 2026.

Key Dates

Recommendation

The company reported record preliminary unaudited revenue for Q4 and full year 2025, significantly increasing year-over-year. Patient growth was exceptional at 103%. The 2026 revenue guidance of $58-$62 million represents a substantial increase of 65% to 76% over 2025, driven by the strategic transition of commercialization rights for Eversense 365, which is also expected to improve gross margins to 50%. Key operational milestones, including FDA IDE approval for the Gemini sensor trial and integration with Sequels twiist system, further strengthen the long-term growth prospects. The strong cash position of $94.3 million provides financial stability. These factors collectively indicate robust performance and a very positive outlook, making it a strong buy.

Keywords

Senseonics, SENS, Continuous Glucose Monitoring, CGM, Diabetes, Medical Technology, Eversense, Financial Results, Revenue, Patient Growth, FDA Approval, Gemini Sensor, Ascensia Diabetes Care, twiist system, Q4 2025, FY 2025, 2026 Guidance